11th Circ. Rips FDA's 'Invisible Ink' Interpretation Of Drug Act

By Rosie Manins (March 23, 2021, 3:10 PM EDT) -- An Eleventh Circuit judge criticized the U.S. Food and Drug Administration's interpretation of the Orphan Drug Act during oral arguments Tuesday over its approval for two companies to make the same rare-disease drug, suggesting statutory text supporting its argument must have been written in "invisible ink."...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!